Phase III trial of CCNU/temozolomide (TMZ) combination therapy vs. Standard TMZ therapy for newly diagnosed MGMT-methylated glioblastoma patients (CeTeg) (BMBF)
Laufzeit: 01.01.2013 - 31.12.2016
Kurzfassung
Phase III trial of CCNU/temozolomide (TMZ) combination therapy vs. Standard TMZ therapy for newly diagnosed MGMT-methylated glioblastoma patients (CeTeg)
